Abstract
Sixty-six consecutive patients who underwent curative resection for rectal cancer were studied prospectively to evaluate the roles of sequential carcinoembryonic antigen (CEA), tissue plasminogen activator (TPA), and carcinomatous antigen 19-9 (Ca 19-9) determinations in the early diagnosis of resectable recurrences. Thirty-three recurrences were detected between 6 and 42 months. CEA, TPA, and Ca 19-9 showed a sensitivity of 72.7 percent, 78.8 percent, and 60.1 percent, respectively, and a specificity of 60.6 percent, 60.6 percent, and 87.9 percent, respectively. In 23 cases the rise in the value of CEA and/or TPA and/or Ca 19-9 was the first sign of recurrences, and the diagnosis was established later by clinical methods. In this group, the lead time was two months for liver metastases and four months for disseminated metastases. As far as the relationship between localization of recurrence and marker level increase is concerned, of 16 hepatic metastases CEA, TPA, and Ca 19-9 showed a sensitivity of 94 percent (P<0.05), 69 percent, and 62 percent, respectively. Of six patients with local recurrences, CEA, TPA, and Ca 19-9 showed a sensitivity of 50 percent, 100 percent (P<0.05), and 83.3 percent, respectively. Of three patients with peritoneal carcinomatosis, CEA, TPA (P<0.05), and Ca 19-9 showed a sensitivity of 0 percent, 100 percent, and 0 percent, respectively. No significant differences were reported among the three markers according to multiple metastases and metachronous polyps. Fourteen patients (42.4 percent) underwent surgical treatment for recurrent disease, and eight of them (57 percent) showed a resectable disease, for a total resectability rate of 24.2 percent. The findings of our study indicate that a followup program based on CEA, TPA, and Ca 19-9 assays is related to an early diagnosis and a good resectability rate for both local and metastatic recurrences from rectal cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wangensteen OH, Lewis FJ, Tongen LA. The second-look in cancer surgery. J-Lancet 1951;71:303–7.
Wangensteen OH, Lewis FJ, Arthelger SW, Muller JJ, Maclean LD. An interim report upon the “second look” procedure for cancer of the stomach, colon and rectum and for “limited intraperitoneal carcinosis”. Surg Gynecol Obstet 1954;99:257–67.
Beart RW, Metzger PP, O'Connell MJ, Schutt AJ. Postoperative screening of patients with carcinoma of the colon. Dis Colon Rectum 1981;24:585–9.
O'Dwyer PJ, Mojzisik C, MacCabe DP, Farra WB, Carey LC, Martin L. Reoperation directed by CEA level: the importance of a thorough preoperative evaluation. Am J Surg 1988;155:227–30.
Bjorklund B. On the clinical use of TPA. Tumor Diagnostik 1980;1:9–20.
Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981;212:53–5.
Ritts RE, Del Villano BC, Go VL, Hebermann RB, Klug TL, Zurawski VR. Initial clinical evaluation of an immunoradiometric assay for Ca 19/9 using the NCI serum bank. Int J Cancer 1984;33:339–45.
Sears HF, Herlyn M, Del Villano BC, Steplewski Z, Kaprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol 1982;2:141–9.
Barillari P, Ramacciato G, De Angelis R,et al. The role of CEA, TPA and Ca 19/9 in the early detection of recurrent colorectal cancer. Int J Colorectal Dis 1989;4:230–3.
Barillari P, Ramacciato G, De Angelis R,et al. The role of CEA, TPA, and Ca 19/9 in the early detection of recurrent gastric cancer. Cancer J 1990;3;139–42.
Fucini C, Tommasi SM, Rosi S,et al. Follow-up of colorectal cancer resected for cure. Dis Colon Rectum 1987;30:273–7.
Martin EW, Cooperman M, Carey TC, Minton JP. Sixty second look procedures indicated primarily by the rise in serial carcino-embryonic antigen. J Surg Res 1980;28:386–94.
Carlsson U, Stewenius J, Ekelund G, Leandoer L, Nosslin B. Is CEA analysis of value in screening for recurrences after surgery for colorectal carcinoma? Dis Colon Rectum 1983;26:369–73.
Finlay IG, MacArdle CS. Role of CEA in detection asymptomatic disseminated disease in colorectal carcinoma. BMJ 1983;286:1242–4.
Martin EW, Minton JP, Care TC. CEA-directed second-look surgery in the asymptomatic patients after primary resection of colorectal carcinoma. Ann Surg 1985;202:310–7.
Attiyeh FF, Stearns MW. Second-look operations based on CEA elevations in colorectal cancer. Cancer 1981;47:2119–25.
Minton JP, Hoen JL, Gerber DM,et al. Results of a 400-patients CEA second-look colorectal cancer study. Cancer 1985;55:1284–90.
Hine KR, Dykes PW. Serum CEA testing in the postoperative surveillance of colorectal carcinoma. Br J Cancer 1984;49:689–93.
Lunde OH, Havig O. Clinical significance of CEA in patients with adenocarcinoma of the colon and rectum. Acta Chir Scand 1982;149:189–93.
Staab HJ, Anderer FJ, Stumpf E, Hornung A, Fisher R, Kleninger G. Eighty-four potential second-look operations based on sequential CEA determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg 1985;149:198–204.
Deveney KE, Way LW. Follow-up of patients with colorectal cancer. Am J Surg 1984;148:717–22.
Sugarbaker PH, Gianola FJ, Dwyer A, Neuman NR. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987;102:79–87.
Author information
Authors and Affiliations
About this article
Cite this article
Barillari, P., Bolognese, A., Chirletti, P. et al. Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer. Dis Colon Rectum 35, 471–476 (1992). https://doi.org/10.1007/BF02049405
Issue Date:
DOI: https://doi.org/10.1007/BF02049405